US2013217031A1PendingUtilityA1

Glyceroglycolipid antigen of mycoplasma pneumoniae

45
Assignee: M BIO TECHNOLOGY INCPriority: Jun 14, 2006Filed: Dec 28, 2012Published: Aug 22, 2013
Est. expiryJun 14, 2026(expired)· nominal 20-yr term from priority
Inventors:Kazuhiro MatsudaYuko Shingu
G01N 33/569C07H 15/06C12P 19/44C07K 16/12G01N 2469/20C07K 16/1253C07H 15/04G01N 2405/00C12P 7/6463G01N 2400/50G01N 2333/30G01N 2469/10G01N 33/56933
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a novel glyceroglycolipid produced by Mycoplasma pneumoniae . The glyceroglycolipid can be used as a diagnostic marker for a disease caused by Mycoplasma pneumoniae.

Claims

exact text as granted — not AI-modified
1 . A compound represented by the following general formula: 
       
         
           
           
               
               
           
         
         wherein in the formula: when R 1 =OH, R 2 =H, and each R 3  can be independently selected from saturated or unsaturated hydrocarbon groups, or when R 1 =H, R 2 =OH, and R 3  is saturated hydrocarbon groups or salts thereof. 
       
     
     
         2 . The compound according to  claim 1 , wherein R 3  is —(CH 2 ) n CH 3 , wherein  n  is 12, 14, 16 or 18. 
     
     
         3 . The compound according to  claim 1 , wherein said compound is selected from the group consisting of:
 3-O-[(β-D-galactopyranosyl)-(1,6)-(β-D-galactopyranosyl)]-1,2-di-O-acyl-sn-glycerol;   3-O-[(β-D-glucopyranosyl)-(1,6)-(β-D-galactopyranosyl)]-1,2-di-O-acyl-sn-glycerol;   and salts thereof.   
     
     
         4 . A composition comprising the compound according to  claim 1  and a carrier thereof. 
     
     
         5 . A diagnostic agent for detection of a disease caused by  Mycoplasma pneumoniae , which comprises the compound according to  claim 1  and a carrier thereof. 
     
     
         6 . The diagnostic agent according to  claim 5 , wherein said disease is selected from the group consisting of:  mycoplasma  pneumonia, asthma and a nervous disease. 
     
     
         7 . A diagnostic kit for detection of a disease caused by  Mycoplasma pneumoniae , which comprises the compound according to  claim 1  and a carrier thereof. 
     
     
         8 . The diagnostic kit according to  claim 7 , wherein said disease is selected from the group consisting of:  mycoplasma  pneumonia, asthma and a nervous disease. 
     
     
         9 . A method for diagnosing a disease caused by  Mycoplasma pneumoniae , comprising the steps of:
 i. bringing the compound according to  claim 1  into contact with a sample from a subject; and   ii. immunologically detecting or measuring an antibody to the compound according to  claim 1  in the sample.   
     
     
         10 . The diagnostic method according to  claim 9 , wherein said disease is selected from the group consisting of:  mycoplasma  pneumonia, asthma and a nervous disease. 
     
     
         11 . The diagnostic agent according to  claim 5 , wherein the compound has galactose at the nonreducing terminus. 
     
     
         12 . The diagnostic agent according to  claim 5 , wherein the compound has glucose at the nonreducing terminus. 
     
     
         13 . An antibody specifically binding to a compound represented by the following general formula: 
       
         
           
           
               
               
           
         
         wherein in the formula: when R 1 =OH, R 2 =H, and each R 3  can be independently selected from saturated or unsaturated hydrocarbon groups, or when R 1 =H, R 2 =OH, and R 3  is saturated hydrocarbon groups or salts thereof. 
       
     
     
         14 . The antibody according to  claim 13 , wherein R 3  is —(CH 2 )CH 3  wherein  n  is 12, 14, 16 or 18. 
     
     
         15 . The antibody according to  claim 13 , wherein said antibody specifically binds to a compound selected from the group consisting of:
 3-O-[(β-D-galactopyranosyl)-(1,6)-(β-D-galactopyranosyl)]-1,2-di-O-acyl-sn-glycerol;   3-O-[(β-D-glucopyranosyl)-(1,6)-(β-D-galactopyranosyl)]-1,2-di-O-acyl-sn-glycerol;   and salts thereof.   
     
     
         16 . The antibody according to  claim 13 , wherein said antibody is a monoclonal antibody. 
     
     
         17 . A composition comprising the antibody according to  claim 13  and a carrier thereof. 
     
     
         18 . A diagnostic agent for detection of a disease caused by  Mycoplasma pneumoniae , which comprises the antibody according to  claim 13  and a carrier thereof. 
     
     
         19 . The diagnostic agent according to  claim 18 , wherein said disease is selected from the group consisting of:  mycoplasma  pneumonia, asthma and a nervous disease. 
     
     
         20 . A kit for detecting  Mycoplasma pneumoniae , which comprises the antibody according to  claim 13  and a carrier thereof. 
     
     
         21 . A kit for diagnosing a disease caused by  Mycoplasma pneumoniae , which comprises the antibody according to  claim 13  and a carrier thereof. 
     
     
         22 . The kit according to  claim 21 , wherein said disease is selected from the group consisting of:  mycoplasma  pneumonia, asthma and a nervous disease. 
     
     
         23 . A method for detecting the presence of  Mycoplasma pneumoniae , comprising the steps of:
 i. bringing the antibody according to  claim 13  into contact with a sample; and   ii. immunologically detecting binding between an antigen substance in the sample and the antibody according to  claim 13 .   
     
     
         24 . A method for diagnosing a disease caused by  Mycoplasma pneumoniae , comprising the steps of:
 i. bringing the antibody according to  claim 13  into contact with a sample from a subject; and   ii. immunologically detecting binding between an antigen substance in the sample and the antibody according to  claim 13 .   
     
     
         25 . The method according to  claim 24 , wherein said disease is selected from the group consisting of:  mycoplasma  pneumonia, asthma and a nervous disease. 
     
     
         26 . The compound according to  claim 1 , wherein said compound is an isolated natural compound derived from  Mycoplasma pneumoniae.    
     
     
         27 . The compound according to  claim 1 , wherein said compound is a synthesized compound. 
     
     
         28 . The compound according to  claim 1 , wherein R 3  is —(CH 2 ) n CH 3 , wherein n is 14 or 16. 
     
     
         29 . The diagnostic kit according to  claim 7 , wherein the compound has galactose at the nonreducing terminus. 
     
     
         30 . The diagnostic kit according to  claim 7 , wherein the compound has glucose at the nonreducing terminus. 
     
     
         31 . The diagnostic method according to  claim 9 , wherein the compound has galactose at the nonreducing terminus. 
     
     
         32 . The diagnostic method according to  claim 9 , wherein the compound has glucose at the nonreducing terminus. 
     
     
         33 . The antibody according to  claim 13 , wherein R 3  is —(CH 2 ) n CH 3 , wherein n is 14 or 16.

Join the waitlist — get patent alerts

Track US2013217031A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.